Cost-Effectiveness of Pixantrone for the Third-/Fourth-Line Treatment of Aggressive Non-Hodgkin’s Lymphoma in Portugal
Abstract
Authors
J Félix B Vandewalle V Andreozzi J Almeida N Silva C Ferreira D Ferreira A Amorim D Doering N Branscombe